Back to Search Start Over

Pre-Clinical Model to Study Recurrent Venous Thrombosis in the Inferior Vena Cava.

Authors :
Andraska EA
Luke CE
Elfline MA
Henke SP
Madapoosi SS
Metz AK
Hoinville ME
Wakefield TW
Henke PK
Diaz JA
Source :
Thrombosis and haemostasis [Thromb Haemost] 2018 Jun; Vol. 118 (6), pp. 1048-1057. Date of Electronic Publication: 2018 Apr 25.
Publication Year :
2018

Abstract

Background: Patients undergoing deep vein thrombosis (VT) have over 30% recurrence, directly increasing their risk of post-thrombotic syndrome. Current murine models of inferior vena cava (IVC) VT model host one thrombosis event.<br />Objective: We aimed to develop a murine model to study IVC recurrent VT in mice.<br />Materials and Methods: An initial VT was induced using the electrolytic IVC model (EIM) with constant blood flow. This approach takes advantage of the restored vein lumen 21 days after a single VT event in the EIM demonstrated by ultrasound. We then induced a second VT 21 days later, using either EIM or an IVC ligation model for comparison. The control groups were a sham surgery and, 21 days later, either EIM or IVC ligation. IVC wall and thrombus were harvested 2 days after the second insult and analysed for IVC and thrombus size, gene expression of fibrotic markers, histology for collagen and Western blot for citrullinated histone 3 (Cit-H3) and fibrin.<br />Results: Ultrasound confirmed the first VT and its progressive resolution with an anatomical channel allowing room for the second thrombus by day 21. As compared with a primary VT, recurrent VT has heavier walls with significant up-regulation of transforming growth factor-β (TGF-β), elastin, interleukin (IL)-6, matrix metallopeptidase 9 (MMP9), MMP2 and a thrombus with high citrullinated histone-3 and fibrin content.<br />Conclusion: Experimental recurrent thrombi are structurally and compositionally different from the primary VT, with a greater pro-fibrotic remodelling vein wall profile. This work provides a VT recurrence IVC model that will help to improve the current understanding of the biological mechanisms and directed treatment of recurrent VT.<br />Competing Interests: J.A.D. is on the Board of Directors of the American Venous Forum, as a Research Council Chair and Member of the ISTH-SSC Board. All the other authors report no conflict of interest.<br /> (Schattauer GmbH Stuttgart.)

Details

Language :
English
ISSN :
2567-689X
Volume :
118
Issue :
6
Database :
MEDLINE
Journal :
Thrombosis and haemostasis
Publication Type :
Academic Journal
Accession number :
29695021
Full Text :
https://doi.org/10.1055/s-0038-1645855